Hauptmenü
  • Autor
    • Geier, Martina
    • Bachler, Thorsten
    • Hanlon, Steven
    • Eggimann, Fabian
    • Kittelmann, Matthias
    • Weber, Hansjorg
    • Lutz, Stephan
    • Wirz, Beat
    • Winkler, Margit
  • TitelHuman FMO2-based microbial whole-cell catalysts for drug metabolite synthesis
  • Volltext
  • DOI10.1186/s12934-015-0262-0
  • Persistent Identifier
  • Erschienen inMicrobial Cell Factories
  • Band14
  • Erscheinungsjahr2015
  • Heft1
  • LicenceCC-BY
  • ISSN1475-2859
  • ZugriffsrechteCC-BY
  • Download Statistik303
  • Peer ReviewNein
  • AbstractBACKGROUND:Getting access to authentic human drug metabolites is an important issue during the drug discovery and development process. Employing recombinant microorganisms as whole-cell biocatalysts constitutes an elegant alternative to organic synthesis to produce these compounds. The present work aimed for the generation of an efficient whole-cell catalyst based on the flavin monooxygenase isoform 2 (FMO2), which is part of the human phase I metabolism.RESULTS:We show for the first time the functional expression of human FMO2 in E. coli. Truncations of the C-terminal membrane anchor region did not result in soluble FMO2 protein, but had a significant effect on levels of recombinant protein. The FMO2 biocatalysts were employed for substrate screening purposes, revealing trifluoperazine and propranolol as FMO2 substrates. Biomass cultivation on the 100L scale afforded active catalyst for biotransformations on preparative scale. The whole-cell conversion of trifluoperazine resulted in perfectly selective oxidation to 48mg (46% yield) of the corresponding N1-oxide with a purity >98%.CONCLUSIONS:The generated FMO2 whole-cell catalysts are not only useful as screening tool for human metabolites of drug molecules but more importantly also for their chemo- and regioselective preparation on the multi-milligram scale.